The GW VRU Director, Dr. David Diemert, co-authored an article assessing the value of public health, economic, and societal value of developing a vaccine to prevent and reduce the transmission of Schistosomiasis. Endemic in 78 countries, it is estimated that approximately 236 million people were treated for Schistosomiasis in 2019. This article evaluates the global public health need for a vaccine.
Vaccine Value Profile for Schistosomiasis
Latest News
Health officials have confirmed a new Ebola outbreak in the Democratic Republic of Congo’s Ituri province, where at least 65 people have died and 246 suspected cases have been identified. Authorities are especially concerned because the outbreak may involve a non-Zaire strain of the virus, meaning…
The GW VRU is a site for a clinical trial to examine Pfizer's new C. diff vaccine.
This was a phase 2, randomized, open-label, non-placebo controlled trial to evaluate two partial doses o the Modified Vaccinia Ankara-Bavarian Nordin (MVA-BN) vaccine for protection against mpox.